Dr. Hafkin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
PO Box 29750
Austin, TX 78755Phone+1 512-375-3485
Education & Training
The University of Texas Health Science Center at San AntonioClass of 1973
Certifications & Licensure
TX State Medical License 1973 - 2019
CA State Medical License 1977 - 2015
Clinical Trials
Publications & Presentations
PubMed
- 23 citationsAbsence of a Pharmacokinetic Interaction Between Intravenous Theophylline and Orally Administered LevofloxacinLee G. Gisclon, Christopher R. Curtin, Cynthia L. Fowler, R. Rex Williams, Barry Hafkin
Journal of Clinical Pharmacology. 1997-08-01 - 106 citationsComparison of Length of Hospital Stay for Patients with Known or Suspected Methicillin‐Resistant Staphylococcus Species Infections Treated with Linezolid or Vancomycin...Zhiming Li, Richard J. Willke, Lionel A. Pinto, Brian E. Rittenhouse, Michael J. Rybak
Pharmacotherapy. 2001-03-01 - 313 citationsHematologic Effects of Linezolid: Summary of Clinical ExperienceStanton L. Gerson, Sheldon L. Kaplan, Jon B. Bruss, Vu Le, Felix M. Arellano
Antimicrobial Agents and Chemotherapy. 2002-08-01
Press Mentions
MicuRx Enrolls First Patient in a Phase 2 Clinical Trial in U.S. For Novel Antibiotic, Contezolid AcefosamilNovember 26th, 2018
MicuRx Announces Receipt of FDA’s QIDP and Fast Track Designations for Contezolid and Contezolid AcefosamilSeptember 21st, 2018- MicuRx Initiates Phase 1 Clinical Trial in U.S. For Novel Antibiotic Agent MRX-4November 30th, 2016
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
